An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
about
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsTherapeutic Potential of Tricyclo-DNA antisense oligonucleotidesIntegrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersRNA therapeutics: RNAi and antisense mechanisms and clinical applicationsFuture microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse.Harnessing the integrated stress response for the treatment of multiple sclerosis.Long noncoding RNAs in prostate cancer: overview and clinical implications.Splice-switching antisense oligonucleotides as therapeutic drugsTargeted killing of myofibroblasts by biosurfactant di-rhamnolipid suggests a therapy against scar formation.Lessons from non-canonical splicingMutant CAG Repeats Effectively Targeted by RNA Interference in SCA7 Cells.The Emerging Role of RNA as a Therapeutic Target for Small Molecules.Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.Long Non-coding RNAs and their Role in Metastasis.Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.From the RNA world to the clinic.Non-coding RNAs as drug targets.Therapeutic targeting of splicing in cancer.Biological applications of xeno nucleic acids.Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials.EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications.Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames.Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides.Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication.DNA damage response inhibition at dysfunctional telomeres by modulation of telomeric DNA damage response RNAs.Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.Targeting Amyloid-β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β Production.Quantitative determination of a siRNA (AD00370) in rat plasma using peptide nucleic acid probe and HPLC with fluorescence detection.
P2860
Q28067081-69E555BF-F677-4BB3-9B37-A0FA04E3660FQ28818017-ADD6AAC4-28B3-4050-BAE1-DBA06BC2B106Q28821280-D4C91877-BE27-4471-8D9D-D46653ED7704Q28829240-A8CA1F33-30E8-48B0-8BAD-3903BAABA2B0Q30357091-8A0234A6-E1A6-4A98-AAC9-864C148575B8Q30832682-EC486294-979D-451E-B6CB-EA8FB3D02055Q36689566-3C7CABAF-EAFD-4B79-B985-C0CB6FD9A1F7Q37113177-4DB174D6-6C41-4474-93CE-EB291CB02D20Q37211004-6E036038-3F20-484B-B20C-3C383C36F369Q37454142-1FC1CA24-F631-4C53-A9B7-37A8320A65BEQ37499331-B666F5A6-11FB-4AD8-9CBC-5E1A4D552A82Q37539531-425A1D5E-B5BB-459B-824E-86B34E1917E9Q38410949-01B5AB5A-B147-4FE6-B73A-B97589E61FDAQ38734734-B9674ACB-0DAD-4E2F-A687-3C4877EC79BDQ38735423-B4A77B91-72F6-4BA4-88EC-D1328A24DEFFQ38818070-2D3811AB-15AE-460A-B329-2F283ED8A0D1Q38829627-3CEB9720-ADD4-4234-990F-9000A430EC3BQ38851919-B443590F-52F6-49F8-8806-63B51C044098Q38904908-15F96FB4-D70E-4C74-96C1-0E2267690643Q38948363-716FC7D0-42C8-4F9B-A71E-8181DBA3D239Q39003630-40D8F9CB-3577-47ED-AFD8-302B09A4B85AQ39021948-95A0CC6C-2CB4-4F4A-A106-2B2A90DE0AFAQ39109931-BC2BF43D-C808-4C88-8714-55BE07C1A946Q39297820-5B6A9C8B-B8AF-42C8-B3D7-6A30C19EDEBDQ39390082-FE978371-65FE-4079-BC23-662950751515Q41106058-7D36564D-2CBE-4630-B0C9-DFD2CB91AB79Q41387647-D512B72F-C655-4B10-B372-EE004BAA1323Q41608170-C426B5F6-EB60-49FB-A48F-FA67FBA56D51Q41769180-654F71FF-E974-4911-81E2-EBF6C4F5F623Q42069602-9FD19DCD-86BD-4968-B3B0-4DF1290FBFAFQ47581752-1BBF9439-636F-482F-9AF2-B90A9D8269C6Q47606968-87D8674A-93FC-44EF-84F5-F7CE1FAAD8B3Q49519966-220706D3-D063-459A-9627-3646FDB4C153Q52608528-B37D1E27-B734-4983-8333-9139C1F400E0Q52720869-8CC6FBD1-8D77-4783-827B-6E74C8739F5BQ54477220-59ED9CF0-01D2-46D4-B947-3CABE5BE299C
P2860
An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
An overview of the clinical ap ...... s for RNA-targeting therapies.
@en
type
label
An overview of the clinical ap ...... s for RNA-targeting therapies.
@en
prefLabel
An overview of the clinical ap ...... s for RNA-targeting therapies.
@en
P1476
An overview of the clinical ap ...... s for RNA-targeting therapies.
@en
P2093
Graham McClorey
P356
10.1016/J.COPH.2015.07.005
P577
2015-08-12T00:00:00Z